FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Mcginniss, J., Pouliot, J., Lee, S., Seebach, F., Lowy, I., Gullo, G., & Rietschel, P. (2021). FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951. https://doi.org/10.1016/j.jtho.2021.08.217
Authors:
Igor Bondarenko
Ahmet Sezer
Saadettin Kılıçkap
Mahmut Gümüş
Mustafa Özgüroğlu
Miranda Gogishvili
Hacı Mehmet Türk
İrfan Çiçin
Dmitry Bentsion
Oleg Gladkov
Philip R. Clingan
Virote Sriuranpong
Naiyer A. Rizvi
Jennifer McGinniss
J-F. Pouliot
S. Lee
Frank Seebach
Israel Lowy
Giuseppe Gullo
Petra Rietschel
Affiliated Authors:
Naiyer A. Rizvi
Publication Type:
Article
Unique ID:
10.1016/j.jtho.2021.08.217
Publication Date:
Data Source:
OpenAlex

Record Created: